| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | 0.1 |
| Net income | -2.8 | -3.1 |
| EPS (diluted, $ a share) | $-0.06 | $-0.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +12.4% |
|---|
10-Q filed with the SEC, NASDAQ: MNOV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Medicinova Inc: key numbers
- Share price
- $1.34Close, Nov 16
- Market cap
- $68.7M
- Shares outstanding
- 51.23MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Medicinova Inc
All →Medicinova Leadership Change
Jason Kruger resigned as Chief Financial Officer, principal financial officer, and principal accounting officer effective November 10, 2026. In response, the Board appointed President and CEO Yuichi Iwaki to serve as interim CFO and acting principal financial/accounting officer until a successor is named. Dr. Iwaki will not receive additional compensation for the interim role.
Medicinova Other 8-K Filing
MediciNova, Inc. entered into a first amendment to its office lease with Newport Gateway Office LLC to extend the lease term for its principal executive offices. The amendment extends the expiration date from January 31, 2027, to April 30, 2030, and includes scheduled rent increases beginning in February 2027.
- Counterparty
- Newport Gateway Office LLC
- Term
- through April 2030